Myriad Genetics Q3 Adj. EPS $(0.11) Beats $(0.20) Estimate, Sales $202.700M Beat $191.329M Estimate
Benzinga Newsdesk 8 hours ago
NewsEarningsEarnings Beats
Myriad Genetics (NASDAQ:MYGN) reported quarterly losses of $(0.11) per share which beat the analyst consensus estimate of $(0.20) by 45 percent. The company reported quarterly sales of $202.700 million which beat the
Myriad Genetics (NASDAQ:MYGN) reported quarterly losses of $(0.11) per share which beat the analyst consensus estimate of $(0.20) by 45 percent. The company reported quarterly sales of $202.700 million which beat the analyst consensus estimate of $191.329 million by 5.94 percent. This is a 1.46 percent decrease over sales of $205.700 million the same period last year.